Global footprint BICO has a broad international installed base with 53,600+ instruments in over 65 countries and services 3,500 laboratories, including top pharma companies. This signals cross-sell and upsell opportunities across geographies and across multiple brands and software solutions.

Automation and data The company combines automation, intelligence, and data to accelerate life-science discovery. Prospects investing in lab automation, data analytics, or lab digital twins are likely to be receptive to BICO’s integrated hardware, software, and services.

Pharma focus BICO’s products and solutions are already deployed in世界’s top 20 pharmaceutical companies, indicating strong credibility with large biotech and pharma accounts and potential for expansion within R&D and manufacturing operations.

Scale and collaboration With a mission to connect labs and accelerate timelines, there are opportunities to partner on large-scale adoption projects, multi-site deployments, and enterprise licensing for software, analytics, and support across global lab networks.

Growth signals Being listed on Nasdaq Stockholm and a broad reference base imply financial stability and growth ambition, suggesting prospects for expanding into new verticals, upgraded instrumentation, and premium service contracts to bolster recurring revenue.